Articles tagged with Viral Gene Delivery
Researchers at Duke University Medical Center have delivered therapeutic genes to a rabbit's heart, boosting its function and increasing sensitivity to heart-stimulating drugs. The breakthrough is a key step towards developing a genetic treatment for congestive heart failure.
Scientists have discovered the gene responsible for triggering embryonic cells in the inner ear to develop into sound- and motion-sensing hair cells. The Math1 gene signals precursor cells in the inner ear to become hair cells, which cover inner ear surfaces like wheat in a Kansas field.
Researchers at University of Pittsburgh Medical Center successfully controlled incontinence in animal model of diabetes using gene therapy approach. The treatment, involving delivery of nerve growth factor gene via modified herpes virus, showed promising results by repairing damaged bladder nerves and improving bladder function.
Researchers at UPMC have successfully conducted the world's first in vivo gene therapy for hemophilia A using a modified retrovirus to deliver the FVIII gene. The treatment aims to permanently restore clotting factor production, reducing costs and complications associated with the disease.
Researchers at Rice University and the University of Texas-Houston Health Science Center have tracked the path that a polymer-DNA complex takes through a cell to its nucleus, where the new DNA can be read. This study improved our understanding of gene delivery and provided new knowledge for designing better nonviral carriers.
Researchers have successfully delivered beta-endorphin genes into the sheath of tissue surrounding the spinal cord, reducing hyperalgesic pain sensation in animal models. The study's simplified approach and selective therapeutic effect suggest potential applications for treating various spinal cord and brain disorders.
Researchers have successfully tested a new gene therapy approach to block certain pain responses in mice. The treatment uses a herpes virus containing a gene that triggers production of a pain-blocking protein, providing long-term potential for pain relief.
Scientists have identified a gene called Pitx1 that can partially transform the upper limb of a vertebrate into a structure resembling its lower limb. The study found that Pitx1 is one of three genes thought to play a role in giving upper and lower extremities their identity.
Researchers have found a secondary barrier in the brain that prevents certain drugs from reaching tumors and neurological disorders. The barrier is called the basement membrane and traps stealth agents while allowing others to pass through, highlighting challenges for gene therapy and drug delivery.
Researchers successfully modified adenovirus, a common cold virus, to carry corrective genes to defective cells. The modified virus persisted for over two months in mice, overcoming a major barrier to widespread use of adenovirus as a genetic delivery vehicle.
A new study reveals that alpha V beta 5-integrins on cell surfaces facilitate the entry of genetically engineered AAV viruses into cells, allowing for efficient gene delivery. This understanding can lead to improved gene therapy methods and enhanced chances of successful treatment outcomes.
Scientists have developed a novel gene therapy system that uses a molecular rheostat to control the activity of therapeutic genes. This system allows for precise dosage control and can be achieved through oral administration of a simple pill.
A team of UI researchers has found a way to permanently deliver therapeutic genes to the lungs of patients with cystic fibrosis. The method uses a retrovirus that integrates into host DNA, allowing the gene to be reproduced in cells. This could lead to a permanent cure for CF and other genetic lung diseases.
University of North Carolina researchers have successfully used an antibiotic-like compound to externally regulate a gene implanted in the brain using AAV technology. This breakthrough suggests that gene therapy may eventually be feasible for human brain disorders such as Parkinson's disease and epilepsy.
University of Michigan scientists have developed a new generation of viral vectors that deliver the dystrophin gene to the muscles of adult mice with muscular dystrophy. The new vectors, called 'gutted' viruses, are stripped of most of their original genes to make room for the large dystrophin gene and reduce immune response.
Researchers at Washington University School of Medicine have created a way to create harmless vectors from harmful viruses. They showed that the vectors are efficient couriers of genes and can be used to study gene regulation and functions, as well as deliver DNA vaccines.
Researchers discover that the CFTR protein acts as a receptor for Salmonella typhi, allowing it to be ingested and cleared from the body. This finding suggests that cystic fibrosis gene carriers may have protection against typhoid fever due to their abnormal CFTR protein.
Researchers at the University of Pittsburgh have constructed a novel delivery system for gene therapy of liver disorders, using a reconstituted chylomicron remnant (RCR) that can safely transport genes to target cells. The system has resulted in extended production of therapeutic proteins in animal models.
Imperial College researchers are building artificial viruses from DNA, protein, and fat that can bypass the patient's immune system. These artificial viruses have shown great promise for gene therapy in corneal transplants, particularly for children at high risk of graft failure.
A new delivery system may allow for more precise control over where new genes are inserted into an organism's chromosomes, improving gene therapy. The approach uses parvoviruses to target specific locations on the chromosomes, reducing the risk of genes causing harm or functioning poorly.
Researchers successfully transferred a normal human beta globin gene into mice bone marrow cells, achieving long-term expression and high levels of production. This breakthrough holds promise for the treatment of sickle cell disease and beta thalassemia.
University of Michigan scientists develop viral vector delivering dystrophin gene to adult mice with muscular dystrophy, inducing high levels of normal dystrophin protein for several months. The breakthrough could pave the way for effective gene therapy treatment for Duchenne muscular dystrophy.
Researchers successfully delivered genes encoding dopamine-producing enzymes into the brains of rats with induced Parkinson's disease, significantly reducing abnormal rotational movement. The treatment showed greater improvement when both genes were used together.
Researchers at Johns Hopkins Medicine have successfully delivered genes to nearly 100% of muscle cells in a rabbit heart using a disabled adenovirus as a carrier. This breakthrough could pave the way for gene therapy to treat various heart diseases, including congestive heart failure and familial hypertrophic cardiomyopathy.
Researchers successfully used a harmless virus to deliver a normal gene into muscle cells in animals and humans, producing the enzyme for at least three months. This breakthrough could lead to a single treatment for children with Pompe's disease, an inherited fatal heart condition.
Researchers have developed a gene therapy technique that can produce and secrete proteins into the bloodstream indefinitely, without the need for viral delivery systems. This could drastically decrease the cost of treatments for certain types of anemia, which affect over 140,000 people in the US annually.
Researchers have identified the gene responsible for Chediak-Higashi syndrome, a fatal childhood disease that weakens the immune system and increases cancer risk. The discovery could lead to new treatments and diagnostic tests for patients with cancer or autoimmune disorders like lupus.